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ABSTRACT Radioligand binding experiments and single channel recordings demonstrate that verapamil interacts with the
ryanodine receptor Ca2+ release channel of the sarcoplasmic reticulum of rabbit skeletal muscle. In isolated triads, verapamil
decreased binding of [3HjRyanodine with an IC50 of -8 ,uM at an optimal pH 8.5 and pCa 4.3. Nitrendipine and d-cis-diltiazem
did not interfere with binding of [3H]Ryanodine to triads, suggesting that the action of verapamil does not involve the
dihydropyridine receptor. Single channel recordings showed that verapamil blocked Ca2+ release channels by decreasing
open probability, duration of open events, and number of events per unit time. A direct interaction of verapamil with the
ryanodine receptor peptide was demonstrated after purification of the -400 kDa receptor protein from Chaps-solubilized
triads. The purified receptor displayed high affinity for [3HlRyanodine with a Kd of -5 nM and a Bmax of -400 pmol/mg.
Verapamil and D600 decreased [3HlRyanodine binding noncompetitively by reducing the Bmax. Thus the presence of binding
sites for phenylalkylamines in the Ca2+ release channel was confirmed. Verapamil blockade of Ca2+ release channels may
explain some of the paralyzing effects of phenylalkylamines observed during excitation-contraction coupling of skeletal
muscle.
INTRODUCTION
The 175 kDa a, peptide of the dihydropyridine (DHP)
receptor serves as a binding site for three classes of
Ca2'-entry blockers such as dihydropyridines, phenylal-
kylamines, and benzothioazepines (Catterall et al., 1988).
Prototype compounds for the three groups are nitren-
dipine, verapamil, and diltiazem, respectively. In the
transverse tubular membrane of skeletal muscle, the
radioligand binding affinities of Ca2' blockers to the al
receptor fall within the submicromolar range, 1 nM for
nitrendipine (Fosset et al., 1983), 30 nM for verapamil
(Galizzi et al., 1984), and 200 nM for diltiazem (Galizzi
et al., 1986). Although L-type Ca2+ channels of skeletal
muscle are blocked by DHPs at submicromolar concentra-
tions (Valdivia and Coronado, 1990), only a small percent
of DHP binding to the tubular membrane of skeletal
muscle is involved in blockade of Ca2+ currents (Schwartz
et al., 1985). The specific enrichment of DHP receptors in
the tubular membrane (Fosset et al., 1983) and the fact
that the al peptide of the DHP receptor is homologous to
the voltage-gated Na+ channel (Tanabe et al., 1987;
Tanabe et al., 1988; Ellis et al., 1988), suggested that al
may have a voltage-sensing function unrelated to Ca2+
entry into the cell (Rios and Brum, 1987; Tanabe et al.,
1988).
Eisenberg et al. (1983) showed that one such process in
which Ca2'-entry blockers are implicated, other than
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Ca2' entry into the cell, is excitation-contraction cou-
pling. In skeletal muscle, Ca2+ entry through Ca2+
channels does not contribute to muscle contraction (Gonza-
les-Serratos et al., 1982) and removal of external Ca2+
does not immediately affect contraction (Armstrong et
al., 1972). Nevertheless, D600 (methoxyverapamil) was
reported to produce paralysis of skeletal muscle fibers
(Eisenberg et al., 1983). In the presence of phenylal-
kylamines, skeletal muscle turned into a mechanically
refractory state in which fibers did not contract in
response to electrical stimulation or to depolarization by
elevated potassium. Intramembrane charge movement is
also absent in paralyzed fibers, and this has been held as
evidence that D600 uncouples voltage-sensors in the
transverse tubular membrane from Ca2+ release in the
sarcoplasmic reticulum membrane (Hui et al., 1984;
Caputo and Bolanos, 1987; Brewe et al., 1987; Erdmann
and Luttgau, 1989; Fill and Best, 1989). In a recent
study, the phenylalkylamine binding site responsible for
muscle paralysis has been presumed to be on the a1 DHP
receptor because Kd values estimated following recovery
from paralysis after exposure of fibers to D888 (des-
methoxyverapamil) agreed well with the radioligand
binding Kd of [3H]D888 to the DHP receptor (Erdmann
and Luttgau, 1989).
We describe a new class of pharmacologically active
binding sites for phenylalkylamines, specifically vera-
pamil, in skeletal muscle. The site turned out to be
directly on the ryanodine receptor channel of the sarcoplas-
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mic reticulum membrane (Smith et al., 1985, 1986,
1988). This binding site differs from that on DHP
receptors in that neither dihydropyridines nor diltiazem
can replace, or compete with, phenylalkylamines. The
interaction of verapamil with the ryanodine receptor
resulted in an inhibition of [3H]Ryanodine binding. The
alkaloid ryanodine is known to produce paralysis in
skeletal and cardiac muscle (Jenden and Fairhurst, 1969)
and has been found to bind with nanomolar affinity to the
"foot" protein that bridges the gap between the transverse
tubule and the junctional sarcoplasmic reticulum (SR) in
triads of skeletal muscle (Inui et al., 1987; Block et al.,
1988; Lai et al., 1988). A tetramer of this protein is
sufficient to reconstitute ryanodine-sensitive Ca2' release
channels in planar bilayers (Imagawa et al., 1987; Smith
et al., 1988; Ma et al., 1988; Lai et al., 1988). We find
that occupancy of these low affinity sites on the ryanodine
receptor by verapamil leads to inhibition of Ca2' release
channels. This observation is relevant to the in vivo
actions of phenylalkylamines and to studies that use
micromolar levels of verapamil and related derivatives. A
preliminary report of this work appeared in abstract form
(Valdivia and Coronado, 1989; Valdivia et al., 1990).
MATERIALS AND METHODS
Purification of triads from rabbit
skeletal muscle
Triads were purified from adult rabbit white skeletal muscle using the
pyrophosphate variant of Mitchell et al. (1983). The following protease
inhibitors were added during homogenization: Pepstatin A (1 MM),
lodoacetamide (1 mM), phenylmethylsulfonyl fluoride (PMSF, 0.1
mM), Leupeptin (1 AM), and Benzamidine (1 mM). Purified triads
were immediately used or stored for no more than 2 wk at - 800C.
Thawed samples were discarded after use. Routinely, the [3H]PN200-
110 binding capacity was 12 pmol/mg, the [3H]Ryanodine binding
capacity was 9 pmol/mg, and the ATP-dependent Ca2" uptake capacity
was 15 nmol/mg triad protein.
Formation of planar bilayers and
single channel recording
Planar bilayers were composed of brain phosphatidylethanolamine and
brain phosphatidylserine at a 1:1 weight ratio (Avanti Polar Lipids,
Birmingham, AL) dissolved in decane (Aldrich Chemical Co., Milwau-
kee, WI). Bilayers were formed on a 0.3-mm diam hole in a Lexan
polycarbonate partition. Triad preparations (0.1-0.2 mg) were added to
the cis solution composed of 0.25 M CsCI, 10 ,uM CaC12, and 10 mM
Hepes (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) titrated
with TrisHCI (Tris[hydroxymethyl] aminomethane) to pH 7.4. Thus,
Cs' instead of Ca2" was the major carrier of current (Smith et al.,
1988). SR Cl- channels were separated from release channels on the
basis of reversal potential (Ec, = + 37 mV, EC, = -37 mV). In .30%
of vesicle fusions, release channels could be recorded in the absence of
Cl- channels and these cases were used for analysis. The total recording
time was 120 min from three preparations of triads. The trans solution
was the same except the CsCl which was 0.05 M. Cis solution was
connected via an Ag/AgCl electrode and an agar/KCI bridge to the
head-stage input of a List L/M EPC 7 amplifier (List Electronic,
DA-Eberstadt, FRG). Trans solution was held at ground potential using
the same electrode arrangement. Recordings were filtered through a
low-pass Bessel (Frequency Devices, Haverhill, MA) at 1.5 kHz and
digitized at 4 kHz. Acquisition, storage, and analysis were done on a
PC/AT computer using Keithley Instruments Inc.-DAS 570 software
(Cleveland, OH).
Ryanodine binding assay
[3H]Ryanodine binding assays were carried out for 90 min at 360C in
400 1A of 0.15 M NaCl, 50MM CaC12, 20 mM Tris-HCI, pH 8.5 (other
buffers, free Ca2", and pH, are indicated in figure legends).
[3H]Ryanodine (60 mCi/mmol; Du Pont-New England Nuclear, Wil-
mington, DE) was diluted directly into the incubation medium to
achieve concentrations in the saturable range of 1-30 nM. Ca2+-EGTA
buffers containing 1 mM Na2EGTA (ethylenediamine tetraacetic acid)
were used when desired free Ca2, was <100 MM. Free Ca2, concentra-
tions were calculated using a computer program and were verified with a
Ca2+ electrode. The following buffers purchased from Sigma Chemical
Co. (St. Louis, MO) were used for the indicated range of pH, Mes
(2[N-Morpholino] ethanesulfonic acid, pH 6-6.5); Mops (3-[N-
Morpholino] propanesulfonic acid, pH 7-7.5); Tris (Tris[hydroxy-
methyl] aminomethane, pH 8-9; and Caps (3-[Cyclohexyl amino]-l-
propanesulfonic acid, pH 10-11). Verapamil or D600 were delivered
from stock solutions in methanol. Final concentration of methanol in the
incubation media was <1% vol/vol. Same volume of methanol was
always added to control samples and had no effect on [3H]Ryanodine
binding. During incubation, triads (0.1-0.2 mg/ml), solubilized mem-
branes (0.1-0.2 mg/ml) or purified receptor (6-10 Mg/ml) were the last
reagent added to the media. Samples (0.1-0.4 ml) were filtered on
Whatman Inc. GF/B glass fiber filters (Clifton, NJ) and washed twice
with 5 ml ice-cold water. A Brandel M-24R Cell Harvester (Gaithers-
burg, MD) was used for filtration. In assays of solubilized receptor,
filters were soaked for 15 min in 5% polyethylenimine. Nonspecific
binding corresponds to the total binding measured in the presence of 10
,MM unlabeled ryanodine and was subtracted from each sample. Ryano-
dine was purchased from Calbiochem (La Jolla, CA).
Verapamil binding assay
[3H]Verapamil (80 mCi/mmol, Du Pont-New England Nuclear) was
directly diluted into 400 Ml of incubation medium (40mM Tris-HCI, pH
8.5) to achieve concentrations in the range of 2-100 nM. Triads
(0.05-0.1 mg/ml) were the last reagent added. Samples (0.4 ml) were
filtered on Whatman GF/C glass fiber filters and washed twice with 5
ml incubation medium containing 200 mM choline chloride. Binding to
filters (-8% of total binding) was determined separately (always in
parallel experiments) for each concentration of [3H]Verapamil. Nonspe-
cific binding corresponds to the total binding measured in the presence of
10 MM cold verapamil, when [3H]Verapamil concentration was 1-30
nM; or in the presence of 20 ,M cold verapamil when [3H]Verapamil
concentration was 40-100 nM. In displacement experiments of bound
[3H]Verapamil, the cold displacer (verapamil, nitrendipine, ryanodine)
was added from a stock solution in methanol. Same volumes of methanol
added to controls had no effect. Stock solutions prepared by serial
dilution in water gave erroneous results, presumably due to a high
nonspecific binding of drugs to glass test tubes. Dissociation constant
were determined according to Cheng and Prusoff (1973) using the
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relation IC50 = Kd (1 + [L *]05/Kd), where IC50 is the concentration of
inhibitor that induces half-displacement of bound [3H]ligand, [L *]0.5 is
the concentration of free [3H]ligand at half-displacement, K*and Kd are
dissociation constants for receptor and [3H]ligand, and receptor and
unlabeled ligand, respectively. Verapamil and D600 were gifts from
Knoll AG (Ludwigshafen, FRG).
Purification of ryanodine receptor
from Chaps-solubilized triads
Ryanodine receptor was purified on sucrose density gradients. Triads
were resuspended in 0.5% Chaps 13-[(3-Cholamidopropyl)dimethyl-
ammonio] I-propanesulfonate, Sigma Chemical Co.}, 1 M NaCl, 40
mM Tris-Maleate pH 7.4, plus protease inhibitors given above. The
homogenate was incubated 60 min at 0°C and spun at 40,000 g in a
Beckman 70.1 Ti rotor (Fullerton, CA). Solubilization of triads under
these conditions was always >80%. 1.5-ml aliquotes of supernatant were
layered on top of a 32-ml, 5%:20% (wt/vol) linear sucrose gradient
containing 0.3 M NaCl, 40 mM Tris-Maleate pH 7.4, 0.1 mM CaCI2,
2.0 mM Dithiothreitol, 50MuM PMSF, 0.15% Chaps, 0.15% Asolecithin
(soybean phosphatidylcholine; Avanti Polar Lipids). Gradients were
centrifuged at 20,000 g in a SW-28 rotor for 15 h at 4°C. Gradient
fractions were monitored for protein content, SDS-PAGE (Sodium
dodecyl sulfate polyacrylamine gel electrophoresis), and [3H]Ryanodine
binding activity. SDS-PAGE was performed according to the Laemmly
method. Samples were incubated 15 min at 800C in 2% SDS, 2%
,8-mercaptoethanol, 10% glycerol, and 10mM Tris (pH 6.8), and run on
a 5-12% linear polyacrylamide gel gradient. A kit from Bio-Rad
Laboratories (Richmond, CA) was used for silver staining. Molecular
weight standards were myosin, M, 200,000; #-galactosidase, M, 1 16,000;
phosphorylase b, Mr 97,400; bovine albumin, M, 68,000; ovalbumin, Mr
43,000; and carbonic anhydrase, Mr 31,000.
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RESULTS
Verapamil inhibition of
[3H]Ryanodine binding to triads
Ryanodine binding affinity and binding site density are
highly sensitive to key ligands that open or close the Ca2,
release channel, such as Ca2+, Mg2+, nucleotides, ruthe-
nium red, and caffeine (Pessah et al., 1986, 1987; Inui et
al., 1987; Imagawa et al., 1987). In general, ligands that
stimulate [3H] Ryanodine binding also open release chan-
nels whereas ligands that inhibit [3H]Ryanodine binding
also close or block release channels. Fig. 1, A and B
describe the Ca2+ and pH dependence of [3H]Ryanodine
binding to triads and the inhibition of specific binding by
the Ca2+-entry blocker verapamil. The Ca2+ dependence
in the absence of verapamil (Fig. 1 A, open circles) is
described by a bell-shaped curve with a peak at -50 ,M
[Ca2+] and a maximum binding capacity of 7 pmol/mg
protein at 5 nM [3H]Ryanodine (0.15 M KCI, pH 8.5, no
added nucleotides). No specific binding was measured at
[Ca2+] .10mM or [Ca2+] <1 MM. Binding activity at 50
,uM [Ca2+] was optimal at pH 9 (Fig. 1 B, open circles)
and decreased at higher or lower pH. No specific binding
was measured at pH <6 or pH > 1 1. For the stimulatory
part of the pH curve we estimated a pKI of -8.3.
However, the inhibitory phase with a midpoint near pH
10 cannot be clearly ascribed to an ionizable group in the
receptor structure. In strong basic solutions, ryanodine
B
pH
FIGURE I Ca2+ and pH dependence and verapamil inhibition of [3H]Ryanodine binding to skeletal muscle triads. (A) [3H]Ryanodine was incubated
90 min at 360C with 80 ,ug purified triads in 0.15 M NaCI, 20 mM Tris-HCI pH 8.5, and the indicated concentration of free Ca2+. [3H]Ryanodine
concentration was 5 nM (60 mCi/mmol) and the incubation volume was 400 MAl. Open circles correspond to specific binding of [3H]Ryanodine and
open squares to specific binding in 20MuM verapamil added at the beginning of the incubation period. 100% corresponds to 3.9 pmol/mg which was the
highest specific [3H]Ryanodine binding at 50MM free Ca2+. (B) [3H]Ryanodine was incubated 90 min at 36°C with 80 Mg purified triads in 0.15 M
NaCl, 150 ,uM CaC12, and 20 mM buffer at the indicated pH. Buffers were Mes (pH 6-6.5), Mops (pH 7-7.5), Tris (pH 8-9), and Caps (pH 10-11),
titrated with NaOH or HCI. Specific binding of [3H]Ryanodine (open circles), plus 20 IMM verapamil (open squares), or 10 IAM nitrendipine (solid
circles), or 20MuM d-cis-diltiazem (open triangles). 100% corresponds to 5.4 pmol/mg which was the highest specific [3H]Ryanodine binding at 50 ,uM
free Ca2", pH 9. (A), (B) Points are mean of three experiments from separate triad preparations.
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undergoes saponification to yield pyrrole-2-carboxylic
acid and ryanodol, none of which appear to have pharma-
cological activity (see Jenden and Fairhurst, 1969).
To our knowledge, the pH dependence of [3H]Ry-
anodine binding has not been reported previously, al-
though Michalak et al. (1988) noticed that [3H]Ryanodine
binding at pH 8 was higher than that at pH 6.8. On the
other hand, the effect of pH on 45Ca2' release from SR
vesicles and single Ca2' release channels is well known
(Nakamaru and Schwartz, 1972; Shoshan et al., 1981;
Sumbilla and Inesi, 1987; Ma et al., 1988). The Ca2+
dependence shown in Fig. 1 A (measured at pH 8.5)
agreed well with that described in other triad prepara-
tions by Pessah et al. (1986) at pH 7.1 or Imagawa et al.
(1987) at pH 7.4. Our results disagreed with those
reported in heavy SR by Lattanzio et al. (1987), however,
who observed inhibition of binding but no Ca2+-depen-
dent stimulation. Verapamil at a concentration of 20,uM
inhibited binding of [3H]Ryanodine to triads over a wide
range of Ca2+ and pH (Figs. 1, A and B, open squares).
Inhibition was most obvious at micromolar Ca2' and
alkaline pH. At 50,M Ca2+ and pH 8.5, 8,uM verapamil
displaced 50% of the specific binding of [3H]Ryanodine
and 300 AM displaced 96%. At pH 7.0, 20,uM verapamil
displaced -20% of the specific [3H]Ryanodine binding,
whereas 1 ,uM had no effect. Inhibition was specific for
verapamil in that prototype drugs from the two other
groups of Ca2+-entry blockers, nitrendipine (10,uM, Fig.
1 B, solid circles) and diltiazem (20,uM, Fig. 1 B, open
triangles) had no effect. The optimal pH for verapamil
inhibition was consistent with the pH dependence of
[3H]Verapamil binding to transverse tubules (t-tubules)
(Galizzi et al., 1984).
Effect of verapamil is not mediated
by DHP receptors
In skeletal muscle fibers (Block et al., 1988), as well as in
triads purified by the method used here (Mitchell et al.,
1983), there is a physical interaction between the junc-
tional SR and the t-tubule membranes. We therefore
considered the possibility that verapamil inhibited bind-
ing of [3H]Ryanodine indirectly, by binding to the DHP
receptor and causing a conformational change at the
[3H]Ryanodine binding site on the ryanodine receptor.
Fig. 2 shows dose-response curves for verapamil inhibition
of [3H]Ryanodine binding in the presence (open circles)
and absence (solid circles) of 10,uM nitrendipine. Vera-
pamil was only effective at micromolar concentration with
an IC50 of -8 ,uM and furthermore, 10 1uM nitrendipine
did not alter the dose-response curve. We reasoned that if
verapamil inhibited [3H]Ryanodine binding by interact-
ing with the DHP receptor, it should have done so at
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FIGURE 2 Dose-response curve for verapamil inhibition of
[3H]Ryanodine binding to triads. [3H]Ryanodine (5 nM) was incubated
90 min at 360C with 80 ;g purified triads in 0.15 M NaCI, 50MgM CaCl2,
20 mM Tris-HCI pH 8.5, and the indicated verapamil concentrations in
the absence (solid circles) or presence (open circles) of 10 UM
nitrendipine. 100% corresponds to 3.0 pmol of specific [3H]Ryanodine
binding per mg triad protein. Smooth line is a fit with a Hill coefficient
nH= 0.89 and Kd = 10 MM. Points are mean of two (verapamil plus
nitrendipine) or three (verapamil) experiments.
nanomolar concentrations, that is, at doses known to
saturate binding of verapamil to the DHP receptor
(Galizzi et al., 1984; see also Fig. 4 A). Moreover, the
inhibitory effect of verapamil should be abolished by
nitrendipine because nitrendipine alone did not inhibit
[3H]Ryanodine binding (Fig. 1 B, solid circles). Nitren-
dipine, at the concentration tested, is known to displace
>90% of verapamil specifically bound to the DHP recep-
tor (Galizzi et al., 1984). Given that the action of
verapamil was unaffected by occupancy of the DHP
receptor, we concluded that a different class of drug sites
was involved in the inhibition of [3H]Ryanodine binding.
Verapamil inhibition of single Ca2+
release channels
To identify the site of action of verapamil we investigated
its effects on ryanodine-sensitive Ca2' release channels.
Fig. 3 A (control) shows recordings of Ca2+ release
channels obtained by the fusion of triads to planar
bilayers. The polarity of the inserted channels was the
same as in previous studies (Smith et al., 1985), that is,
the myoplasmic side faced into the cis solution and the
intravesicular side faced into the trans solution. This was
confirmed by the cis-activation of channels by ATP and
micromolar Ca2+ which are myoplasmic activators of SR
release channels (Smith et al., 1985, 1986). Instead of
Ca , we used 250 mM CsCl on the cis side and 50 mM
CsCl on the trans side as current carrier. This eliminated
the need for large and unphysiological gradients of trans
Ca2+ which severely decrease the activity of release
channels (Ma et al., 1988). Also Cs+ blocked SR K+
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FIGURE3 Inhibition of Ca2+ release channels by verapamil. (A) Ca2+ release channels at HP +20 mV, 10 MM Ca2+ before (control) or after cis
addition of 50MM verapamil (+verapamil). (B) 100 s of continuous records in control and after addition of verapamil were divided into intervals of
100 ms; P. in each interval is plotted as a bar of length 0-1. Average Po was 0.151 in control and 0.038 after addition of verapamil. (C) PO in each
interval of 5 s was added to that of the previous interval and the cumulative sum plltted as a function of the recording time. (D) Open events of
duration time, t, or longer are plotted as a function of time, t. Number of observations were 11,737 (control) or 3,659 (verapamil).
channels (Coronado and Miller, 1979) and because it has
a higher conductance than Ca2" or Na+ through release
channels (gc/ggc = 2) (Smith et al., 1988), it improved
the signal-to-noise ratio. Channels had a linear current-
voltage relationship with a slope conductance of 450 pS
and a reversal at potentials more negative than -30 mV.
Furthermore, ryanodine at a concentration of 100 nM or
less, produced an irreversible decrease in conductance to
250 pS and an increase in mean open time from 0.5 ms in
control to 50 ms in the presence of ryanodine (not shown).
The ligand gating characteristics of channels in Cs' were
similar to those measured previously in high trans Ca2+
(Smith et al., 1985, 1986, 1988). For example, cis 5 mM
ATP increased channel activity -five-fold, cis 1 mM free
Mg2+ decreased activity 10-fold, and cis 1 gM ruthenium
red decreased activity 100-fold (not shown).
Ca2+ release channels at +20 mV, 10 ,uM free Ca2+,
and pH 7.4 are shown in Fig. 3 A, both before and after
addition of 50 ,M verapamil. Channel activity monitored
over 100 s in each condition had a mean open probability
PO = 0.15 ± 0.10 (SD) in control and decreased to PO =
0.038 ± 0.035 (SD). The most significant kinetic effects
of verapamil were a reduction in the burst time (Fig. 3 B)
and a reduction in the mean open time (Fig. 3 D). Both
contributed to an overall decrease in the number of events
per unit time, shown in Fig. 3 C in a graph of cumulative
PO over time. As indicated by the diary of openings of Fig.
3 B, verapamil produced a significant reduction in the
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number of long openings, that is in the events with high
PO. The length of each bar in Fig. 3 B represents PO during
consecutive sweeps. Each sweep had a duration of 100 ms.
Empty spaces, seen only after addition of verapamil,
corresponded to null sweeps in which no openings were
seen. Successive sweeps containing long openings gave
rise to bursts (see Fig. 3 B, control) which were substan-
tially shortened by verapamil (Fig. 3 B, +verapamil).
Likewise, Fig. 3 D shows that mean duration and total
number of events were reduced from control ropen = 1.9
ms and n = 11,737 events, tor0open C 0.6 and 3,659 events.
Duration of closed events (not shown) increased from
control Tcr1e = 3 and 16 ms to Tcr1,d = 5 and 31 ms after
addition of verapamil. Similar inhibition was seen when 2
mM Ca2, was added to the trans chamber to establish a
Ca2, gradient equivalent to that present across the SR
membrane during constant Ca pump activity (Hassel-
bach and Oetliker, 1983). From these experiments we
concluded that verapamil, albeit at relatively high concen-
trations (>20 ,uM at pH 7.4), stabilized the release
channel in a closed or blocked conformation. This inhibi-
tory effect would explain the reduced affinity of the
receptor for [3H]Ryanodine in the presence of verapamil
because open channels have a much higher affinity for the
alkaloid than closed channels (Pessah et al., 1986, 1987).
Identification of low-affinity sites for
[3H]Verapamil in triads
Low-affinity and high-affinity binding sites for [3H]Ver-
apamil in triads are shown in Fig. 4 A. Inset in Fig. 4 A
corresponds to separation of low and high affinity compo-
nents using Scatchard analysis. A low-density (Bma,, = S
pmol/mg), high-affinity (Kd= 15 nM) class of sites
saturated at 40 nM [3H]Verapamil whereas a high-
density low-affinity component did not exhibit saturation
up to a concentration of 100 nM [3H]Verapamil. When
triads were prelabeled with 7 nM [3H]Verapamil, displace-
ment with unlabeled verapamil was biphasic (Fig. 4 B,
solid circles). Half-maximum displacement of the high
and low affinity components occurred at -20 nM and 5
,uM unlabeled verapamil, respectively. Nitrendipine
(Fig. 4 B, open circles) produced a maximum displace-
ment of 75% of bound [3H]Verapamil with an apparent
Kd of - 1.1 nM and a Hill slope of 0.96. This affinity is the
same as that of [3H]Nitrendipine binding to DHP recep-
tors (Fosset et al., 1983) and suggested that the high
affinity binding of [3H]Verapamil was indeed to the DHP
receptor. Also, the total site density of the high affinity
component (5 pmol/mg, Fig. 4 A) agreed well with the
density of nitrendipine receptors in triads (Fairhurst et
al., 1983). The fraction of bound [3H]Verapamil sensitive
to ryanodine is shown in Fig. 4 B (open triangles).
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FIGURE 4 Binding of [3H]Verapamil to triads and displacement by
unlabeled verapamil, nitrendipine, and ryanodine. (A) Purified triads
(40 tsg) were incubated 60 min at 360C with [3H]Verapamil (80
mCi/mmol) in 400 Al of 40 mM Tris-HCl pH 8.5. Inset shows
Scatchard plot of specifically bound [3H]Verapamil. High affinity site
has a Bmax = 5 pmol/mg and Kd = 15 nM. Solid line is a least squares
regression fit. Dotted lines describe independent binding components.
Points are means of two experiments. (B) [3H]Verapamil (7 nM) was
incubated for 60 min at 360C with purified triads (120 ,ug/ml) and the
indicated concentration of nitrendipine (open circles), verapamil (solid
circles), or ryanodine (open triangles). 100% of specific [3H]Verapamil
binding corresponds to 2.5 pmol/mg triad protein. Points are mean of
three (verapamil), one (nitrendipine), or three (ryanodine) experiments.
Unlabeled ryanodine inhibited up to 30% of specific
binding of [3H]Verapamil at the highest concentration
assayed (300,M ryanodine). Because the ryanodine-
sensitive and the nitrendipine-insensitive fractions were
roughly the same, we concluded that the low affinity
fraction was that responsible for the interaction of vera-
pamil with the ryanodine receptor. Moreover, the appar-
ent Kd for [3H]Verapamil binding to the low affinity
nitrendipine-insensitive site (Fig. 4 B, solid circles) was
estimated as 5 1,M, which is similar to the IC50 for
verapamil inhibition of [3H]Ryanodine binding (8 ,uM,
Fig. 2).
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Verapamil inhibition of
[3H]Ryanodine binding to the purified
ryanodine receptor
Micromolar verapamil has a broad spectrum of action
which includes inhibition of Na+ channels (Frelin et al.,
1982; Sihra et al., 1984), and inhibition of K+ channels in
neurons (Hume, 1985) and heart (Kass, 1982; Kayana
and Katzung, 1984), as well as inhibition of Ca2+
transport across the sarcoplasmic reticulum (reviewed by
Herbette et al., 1982). We therefore contemplated the
possibility that verapamil interacted directly with the
ryanodine receptor. Fig. 5 shows [3H]Ryanodine binding
experiments performed in the receptor purified to homoge-
neity from Chaps-solubilized triads. Using the sucrose
gradient method of Lai et al. (1988) we identified the
purified receptor as a single, =400 kDa polypeptide
sharply distributed between 13.5% and 16.5% wt/vol
sucrose (Fig. 5 A, lane 2). Arrows indicate molecular
weight markers in silver-stained PAGE gels. Polypeptides
of lower molecular weight, suggestive of contamination
or degradation, did not copurify with the receptor but
were abundant in lighter fractions (lane 1). The distribu-
tion of the =400 kDa peptide and the distribution of
[3H]Ryanodine binding activity in the sucrose gradient
was strictly coincidental (not shown). Fig. 5 B (open
circles) shows that the purified receptor displayed high
A t_
affinity [3H] Ryanodine binding to essentially a single site
with Kd = 5 nM and Bm.. = 400 pmol/mg, in agreement
with previous reports using a variety of purification
methods (Inui et al., 1987; Imagawa et al., 1987; Lai et
al., 1988). The binding of [3H]Ryanodine to the purified
receptor in the presence of 30 ,uM D600 (methoxyvera-
pamil) appears in Fig. 5 B (solid circles). The phenylal-
kylamine reduced [3H]Ryanodine binding at all concen-
trations tested. Inhibition was noncompetitive in nature
(Fig. 5 C), inasmuch as the Kd did not change but there
was a decrease in Bmax from 400 to 280 pmol/mg, or
- 1.4-fold. This result suggested that the verapamil bind-
ing site in the purified ryanodine receptor is altogether
distinct from the ryanodine binding site.
Dose-response curves for D600 and verapamil, ob-
tained by incubation of the purified receptor with 5 nM
[3H] Ryanodine and increasing concentrations of the
phenylalkylamine, are given in Fig. 6. D600 (open cir-
cles) inhibited binding with an IC50 of =80 ,1M, whereas
for verapamil (solid circles) the IC50 was =800 ,uM. This
value is 80-fold higher than that measured in intact triads
(Fig. 2). In agreement with this shift, we also failed to
observe phenylalkylamine effects in purified ryanodine
receptor channels up to a concentration of 50 ,uM vera-
pamil (not shown). This was in spite of the fact that the
purified preparation was as active as in previous reports
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FIGURE 5 [3H]Ryanodine binding to the purified ryanodine receptor and inhibition by D600. (A) Silver-stained PAGE gels of 40 j1 of 5% (lane 1, 40
Ag protein) or 15% (lane 2, 3 jg protein) sucrose gradient fractions of Chaps-solubilized ryanodine receptor. A single band of M.W. -400 kDa (lane 2)
was obtained from 13.5% to 16.5% sucrose. (B) Total binding of [3H]Ryanodine to the purified receptor. Fractions pooled from the 13.5% to 16.5%
portion of the sucrose gradient were incubated for 90 min at 360C with the indicated concentrations of [3H]Ryanodine in 300 mM NaCl, 40 mM
Tris-Maleate pH 7.4, 100 AM CaCl2, 2mM Dithiothreitol, 50 AM PMSF, 320 mM Sucrose, 0.15% Chaps, and 0.15% Asolecithin (open circles); or in
the same buffer plus 30MM D600 (solid circles); or in the same buffer plus 10MM unlabeled ryanodine (triangles). D600 or unlabeled ryanodine were
added at the beginning of the incubation period. Receptor concentration was 6 Mg/ml. (C) Scatchard plot of the specific binding of [3H]Ryanodine.
Kd = 5 nM and Bmax = 400 pmol/mg in the absence of D600 (open circles) and Kd = 6 nM and Bmax = 280 pmol/mg in the presence of D600 (solid
circles).
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FIGURE 6 Dose-response curve for verapamil and D600 inhibition of
[3H]Ryanodine binding to the purified ryanodine receptor. Purified
protein (6 ,ug/ml) was incubated 90 min at 360C in 300 mM NaCl, 40
mM Tris-Maleate pH 7.4, 100 MAM CaC12, 2 mM Dithiothreitol, 50 gM
PMSF, 320 mM Sucrose, 0.15% Chaps, and 0.15% Asolecithin plus 5
nM [3H]Ryanodine and the indicated concentration of D600 (open
circles) or verapamil (solid circles). 100% of specific [3H]Ryanodine
binding corresponds to 220 pmol/mg of purified receptor. Points are
mean of two experiments for each phenylalkylamine.
(Ma et al., 1988). Evidently there is a drastic decrease in
affinity for verapamil in the purified protein. This result is
not entirely surprising because the same effect is present
for other ligands of the ryanodine receptor. In the case of
ruthenium red, there is a shift from IC50 = 8 nM in intact
triads to 2.5,M in the purified receptor (Imagawa et al.,
1987), or a 300-fold decrease in affinity. For tetraamine
palladium and tetraamine platinum, two recently de-
scribed inhibitors of the Ca2+ release channel (Ma et al.,
1989), the shift is -200-fold (unpublished results). Also,
the Ca2+ required to inhibit [3H]Ryanodine binding is
50-fold higher in the purified than in the native receptor
(Imagawa et al., 1987).
DISCUSSION
Low-affinity binding sites for
phenylalkylamines in skeletal
muscle
In the present work, we traced a low-affinity phenylal-
kylamine binding site to the ryanodine receptor and
showed that occupancy of this site by verapamil blocked
the release channel. Nitrendipine had no effect on the
verapamil-ryanodine receptor interaction which sug-
gested that DHP receptors were not directly involved. A
functional interaction of DHP receptors and ryanodine
receptors at the triad junction of skeletal muscle has been
previously suspected on several grounds. Such coupling
may account for (a) the influence of DHPs and phenylal-
kylamines on "voltage sensors" of excitation contraction
coupling (Hui et al., 1984; Rios and Brum, 1987; Brewe et
al., 1987; Erdmann and Luttgau, 1989); (b) the copurifi-
cation of ryanodine and DHP receptors in membrane
preparations of cardiac and skeletal muscle (Williams
and Jones, 1983; Knudson et al., 1988); (c) the fact that
the ryanodine receptor is at the same time the Ca2+
release channel and the foot protein that spans the
t-tubule SR junction (Block et al., 1989). Thus, the effects
of Ca2+ antagonists on the ryanodine receptor are impor-
tant because they may represent the means to determine
if a functional coupling exists between the two receptors.
Our results do not rule out the existence of such a complex
but demonstrate that drug occupancy at t-tubule DHP
receptors does not modulate binding of [3H] Ryanodine at
the ryanodine receptor.
Although verapamil and D600 block Ca channels in
heart (Lee and Tsien, 1983) and skeletal muscle (Val-
divia and Coronado, 1989), the pharmacological effects of
phenylalkylamines are not restricted to the inhibition of
DHP-sensitive Ca2+ channels (Herbette et al., 1982;
Kass, 1982; Kayana and Katzung, 1984; Hume, 1985;
Striessnig et al., 1985; Oeken et al., 1986). Particularly
relevant to our findings are previous reports of inhibition
of Ca2+ transport in the SR by D600 and verapamil
(Balzer, 1972; Entman et al., 1972). These effects occur
at concentrations higher than those required to saturate
drug binding to the DHP receptor (>10 ,gM; Nayler et
al., 1972; Watanabe et al., 1974). Furthermore, the
presence in cardiac and skeletal muscle of phenylal-
kylamine binding proteins other than the DHP receptor,
is known. In heart, verapamil receptors are four times
more abundant than DHP receptors and only 30% of
bound verapamil is displaced by nitrendipine (Garcia et
al., 1984). In a solubilized preparation of Ca2+ channels
of skeletal muscle, Horne et al. (1988) showed that
45Ca2+ flux activity assayed in liposomes, and the sensitiv-
ity of channels to verapamil, resided in fractions with
different peptide compositions. The flux activity required
the a I peptide of the DHP receptor, whereas verapamil
sensitivity resided in a fraction which included 165 and 55
kDa proteins distinct from al peptide (Horne et al.,
1988). Thus, besides data shown here, there is additional
biochemical and electrophysiological evidence to support
the existence of pharmacologically active low-affinity
phenylalkylamine binding sites in muscle cells.
Implications for
excitation-contraction coupling
The presence of a phenylalkylamine-sensitive inhibitory
site on the release channel has not been previously
considered in the context of muscle paralysis by D600 and
related phenylalkylamines. Because caffeine opens re-
lease channels (Rousseau et al., 1988) and induces a
contracture even in the presence of D600 (Fill and Best,
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1989), it was thought that phenylalkylamines could block
Ca2+ release without affecting release channels. Caffeine
does not induce a spontaneous contracture however, in
muscle fibers paralyzed with the high affinity phenylal-
kylamine D888 (Erdmann and Luttgau, 1989). Eisenberg
et al. (1983) suggested that D600 blocked contraction at
some step after onset of charge movement and before the
release of Ca2+ from the SR. Brewe et al. (1987) proposed
that D600 interacted directly with the "voltage sensor" on
the t-tubule membrane to stabilize both the inactive form
and the active form of this sensor. Evidence that the al
peptide of the DHP receptor forms part of the putative
voltage sensor has been provided by direct pharmacologi-
cal experiments (Hui et al., 1984; Rios and Brum, 1987;
Ederman and Luttgau, 1989), and by restoration of
contraction in dysgenic mice fibers microinjected with al
cDNA (Tanabe et al., 1988). On the other hand, there are
numerous observations that suggest that occupancy of the
high affinity site in the DHP receptor is not sufficient to
induce muscle paralysis. (a) In microinjected frog fibers,
paralysis may be induced by 30,M D600 but not 20,M
nifedipine (McCleskey, 1985). (b) Cooling of frog fibers
to 70C is a prerequisite for the D600-induced paralysis
(Eisenberg et al., 1983) whereas in the same tissue, the
binding affinity for [3H]Nitrendipine is about the same at
100 or 370C (Jaimovich et al., 1986). The Bma, of
[3H]Nitrendipine however, is highly temperature depen-
dent (Jaimovich et al., 1986). (c) Doses required to block
contraction are two or more orders of magnitude higher
than the radioligand binding affinity of the same com-
pound for the DHP receptor. Verapamil, D600, and D888
bind to the al subunit of the DHP receptor with a Kd of
-30 nM, 40 nM, and 1 nM, respectively (Galizzi et al.,
1986; Sieber et al., 1987; Galizzi et al., 1984), whereas
the concentrations required to block muscle contraction
are 30 ,uM D600 (Eisenberg et al., 1983; McCleskey,
1985); 5-100 ,M D600 (Brewe et al., 1987); or 0.05-5
,uM D888 (Erdmann and Luttgau, 1989).
In the case of DHPs, the discrepancy between ligand-
binding affinities and the electrophysiologically measured
affinities, has been attributed to the membrane potential,
which at rest holds the DHP receptor in a low affinity
state (Bean, 1984; Sanguinetti and Kass, 1984). Whether
a voltage-dependence of binding is also present for phe-
nylalkylamines is not entirely known but it is assumed to
be similar (Erdmann and Luttgau, 1989). On the other
hand, a high phenylalkylamine concentration necessary to
paralyze muscle may reflect the fact that the primary
target of phenylalkylamines, as far as muscle paralysis is
concerned, is not the t-tubule voltage sensor but the
ryanodine receptor channel. It must be admitted however,
that the conspicuous use dependence and temperature
dependence of phenylalkylamine-induced paralysis may
be particularly hard to explain within this hypothesis.
Even if t-tubule voltage sensors are the main site of
action, the block of release channels is practically unavoid-
able, given that micromolar levels of D600 or D890 are
required for paralysis even in skinned muscle fibers
(Donaldson et al., 1984; Fill and Best, 1989). Finally, the
observation that caffeine stimulates [3H] Ryanodine bind-
ing (Pessah et al., 1987) and opens release channels
(Rousseau et al., 1988) whereas verapamil inhibits
[3H]Ryanodine binding (Fig. 1) and blocks release chan-
nels (Fig. 3), suggests that a competitive interaction
between the two ligands is likely to occur when both are
present. A competition between caffeine and phenylal-
kylamines, for stimulatory and inhibitory sites, respec-
tively, in the ryanodine receptor, could account for the
faster rate of recovery from paralysis observed in muscle
fibers treated with D888 plus caffeine (Erdmann and
Luttgau, 1989).
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